BiotechTubeBiotechTube
Home/Pipeline/ARISE Study Program

ARISE Study Program

Undisclosed

Phase 3Completed

Key Facts

Indication
Undisclosed
Phase
Phase 3
Status
Completed
Company
Insmed

About Insmed

Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform lives of patients facing serious diseases. The company has achieved commercial success with approved therapies in the US and EU, while advancing multiple programs through clinical development. Insmed has been consistently recognized as Science magazine's #1 Top Biopharma Employer for five consecutive years and maintains a culture of collaboration and innovation across 9 corporate offices worldwide.

View full company profile

Therapeutic Areas

Respiratory DiseasesRare DiseasesPulmonary Arterial HypertensionBronchiectasisInterstitial Lung Disease

Other Undisclosed Drugs

DrugCompanyPhase
ASPEN Study ProgramInsmedPhase 3
MGL-2086Madrigal PharmaceuticalsPhase 1
Innovative Proprietary/Licensed ProductsLaboratorios Farmaceuticos RoviVarious
Undisclosed Partnered ProgramSepternaDiscovery
Undisclosed Cell TherapyImmix BiopharmaPre-clinical
HTL0039732Nxera PharmaPreclinical
LYT-310PureTech HealthPreclinical
Bispecific (Undisclosed)MacroGenicsPreclinical
Sec61 Portfolio AssetsKezar Life SciencesPreclinical
WTX-518Werewolf TherapeuticsPreclinical
WTX-712Werewolf TherapeuticsPreclinical
Measovir®-based Prophylactic Vaccine (with Unither)OncovitaResearch/Pre-clinical